
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a reduced net loss of $1.14 per share in 2Q25, which was better than analysts' initial estimate of $1.22 per share, indicating improved financial performance. The clinical trial results for OKI-219 showed that the treatment was well-tolerated, with no reports of hyperglycemia and only Grade 1 treatment-related adverse events, signifying a favorable safety profile. This combination of narrowing losses and positive clinical outcomes enhances OnKure’s potential for future growth and strengthens its position in the clinical biopharmaceutical market.
Bears say
OnKure Therapeutics Inc. faces a projected full-year net loss of $4.56 per share for 2025, indicating a worsening financial outlook from the previous estimate of $4.75 per share. The company is exposed to significant risks, including potential negative clinical results for its lead asset, OKI-219, and delays in advancing pipeline candidates, which could hinder future growth and revenue generation. Additionally, challenges in obtaining timely regulatory approvals and competition from other mutant-selective PI3Kα inhibitors further exacerbate concerns about the company's long-term viability and potential dilution risk for shareholders.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares